Artrya Limited (AYA) operates at the intersection of applied artificial intelligence and healthcare, collaborating closely with clinicians to enhance the diagnosis of coronary heart disease and provide comprehensive insights into at-risk patients. The company has pioneered deep-learning algorithms, currently pending regulatory submission for clearance and approval in the US. These advanced algorithms are poised to predict and proactively prevent acute coronary events, marking a significant advancement in cardiovascular care.